News

All News

Press Releases

Media

All Videos

Digital Detail

Independent Corner

Insights

Interviews

Medical World News

Microsites

Peer Exchange

Perfect Consult

Podcasts

Practice Pearls

Student Voices

Webinars/Webcasts

Conferences

Conference Coverage

Conference Listing

Publications

All Publications

Author Submission

Clinical

503B Compounding Pharmacy

ADHD

Allergy

Alzheimer Disease

Anxiety

Asthma

Atopic Dermatitis

Biosimilars

Bipolar Disorder

Brain Health

Breast Cancer

C. Difficile

COPD

COVID Treatment

Cardiovascular Health

Cervical Cancer

Cholangiocarcinoma

Chronic Kidney Disease

Chronic Lymphocytic Leukemia

Colorectal Cancer

Coronavirus

Cough and Cold

Depression

Dermatology

Diabetes

Digestive Health

Dry Eye Disease

Epilepsy

Eye Care

Future of Pharmacy

Gastrointestinal Cancer

Gastrointestinal Health

Gout

Heart Failure

Hematology

Hepatitis

IVIG

Immunization

Immuno-oncology

Infectious Disease

Lung Cancer

Lymphoma

Macular Degeneration

Mental Health

Migraine

Multiple Myeloma

Multiple Sclerosis

Neurology

Neutropenia

Osteoporosis

Ovarian Cancer

Pain Management

Parkinson Disease

Pediatrics

Pharmacy Heroes

Pharmacy Management

Pneumococcal

PrEP

Prostate Cancer

Psoriasis

Psoriatic Arthritis

Reimbursement

Respiratory Syncytial Virus

Rheumatoid Arthritis

Schizophrenia

Skin Cancer

Sleep

Veterinary Pharmacy

Vitamins and Supplements

Weight Management

Women's Health

Zoster

Events

Upcoming Events

Upcoming Webinars

CME/CE

Resources

Cou-Co

Educated Patient

Information for the Pharmacist

Interactive Tools

Partners

Whiteboards

Subscribe

Print Subscription

eNewsletter

Ashley Gallagher is an assistant editor at 

®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.

Articles

Chemotherapy, medication for attention deficit/hyperactivity disorder, glucagon-like peptide-1 agonists for weight loss and diabetes, and local anesthetics were among the drugs most affected by shortages.

Survey: 72% of Pharmacy Technicians’ Workflow Affected by Drug Shortages

Empagliflozin (Jardiance) demonstrated a 28% relative risk reduction, with an absolute risk reduction of 3.6% per patient-year at risk in the treatment of chronic kidney disease.

FDA Approves Empagliflozin for Adults With Chronic Kidney Disease at Risk of Progression

 She is a proud alumna of the University of Massachusetts. She graduated with degrees in Journalism, Art History, and Environmental Conservation.

The people who come to the community pharmacy represent the surrounding population at large, making the pharmacy an ideal place to identify and recruit underrepresented patients.

Community Pharmacy Can Help Solve National Health Equity Challenges Facing Clinical Research  

The House Committee members examined pricing tactics by PBMs and how they are harming patients across the country.

House Committee Hearing Addresses PBMs, Anticompetitive Drug Pricing Tactics

Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.

About Us

Advertise

Contact Us

Editorial Staff

Privacy Policy

Terms & Conditions

Do Not Sell My Information

Pharmacy Times – Pharmacy Practice News and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Spotlight

Hospital

Oncology

Pharmacy Technician

Retail

Student

Clinical Role

Specialty Pharmacy

1rem

Authors

Warnings about the risk of ketoacidosis and serious urinary tract infections have been added to the labels of SGLT2 inhibitors.


Diabetes Drug Label Includes New Risks

Katie Eder, Senior Editor, Pharmacy Times

Articles